Nilotinib Label Update to Include Treatment Discontinuation Recommendations for CML With Sustained Molecular Responses
Dec 25
2017
FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response.